Towards new approaches to disorders of fear and anxiety

Brian George Dias, Emory University
Samiran Banerjee, Emory University
Jared V Goodman, Emory University
Kerry Ressler, Emory University

Journal Title: Current Opinion in Neurobiology
Volume: Volume 23, Number 3
Publisher: Elsevier: 12 months | 2013-06, Pages 346-352
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.conb.2013.01.013
Permanent URL: http://pid.emory.edu/ark:/25593/gj7hc

Final published version: http://dx.doi.org/10.1016/j.conb.2013.01.013

Copyright information:
© 2013 Elsevier Ltd. All rights reserved.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Accessed December 7, 2019 2:33 PM EST
Towards new therapies for disorders of fear and anxiety

By recent estimates, 28% of the U.S. population suffers from some form of anxiety-related disorders during their lifetime [1]. These illnesses result in numerous adverse effects that extend from the impoverishment of the individual’s quality of life to the high financial cost incurred to treat them. Understanding the functioning of the nervous system in a healthy and affected state will aid in the development of treatments for these disorders [2]. While the eventual goal of such investigation is to ameliorate these conditions in humans, a productive and complementary strategy that can pave the way for intervention in humans uses animal models, wherein the etiology and treatment of anxiety-related disorders is studied [3].

Focusing on anxiety- and fear-related disorders, this brief review attempts to synergize the existing state of knowledge in terms of their neural underpinnings, currently used therapeutic intervention, and potential treatments that hold promise for the future using studies that focus on both animals and humans.

Anxiety and Fear: Operational Definitions

While the physical and psychological manifestations of anxiety and fear appear to share commonalities, they are in fact two independent entities that merit operational definitions. Anxiety is characterized as a state of being that arises from general and non-specific stimuli that are perceived as being potentially threatening in the future. This perception often results in an apprehensive mood accompanied by increased arousal and vigilance, which when taken to an extreme, persist for extended periods of time. In contrast, fear is stimulated by
specific stimuli and results in active defensive responses that gradually subside when the
specific stimulus is no longer present [4]. Clinically, fear can be thought of as mirroring the
response to a specific cue (e.g. the fear of snakes), while anxiety is a more long-lasting
phenomenon that is not specific to overt cues.

Anxiety in laboratory rodents is often measured using crude behavioral assays such as the
Elevated Plus Maze, while fear to specific cues is modeled by employing Pavlovian
conditioning to cues such as tones or lights [5]. Recently, nuanced experimental paradigms
that more faithfully represent the aforementioned operational distinctions between anxiety
and fear have been employed in rats. Anxiety can be modeled using both light- and dark-
enhanced startle paradigms, context conditioning, and by exploiting the unpredictability of
aversive events (such as mild shock) [6,7]. In contrast, fear can be elicited and measured
using paradigms that include but are not limited to cue-specific conditioning, and verbal
threat in humans [8]. Further discussion of details about how best to model anxiety and fear
in rodents and humans is outside the scope of this review, and there are other excellent
comprehensive reviews [9–12]. The need to operationally define anxiety vs fear arises due
to the fact that these two behavioral states are mediated by shared as well as independent
sub-systems in the brain, and can be treated with independent therapeutic strategies [13].

**Anxiety and fear in the brain-from the connectome to the epigenome**

**Neural circuitry underlying anxiety and fear**

As with any neuropsychiatric disorder, a constellation of brain regions underlie anxiety- and
fear-like states [14••, 15•, 16–18]. At the core of this is thought to be the “extended
amygdala” which includes the central (CeA) and medial (MeA) nuclei of the amygdala and
the bed nucleus of the stria terminalis (BNST) (Figure 1). The extended amygdala is
responsive to afferent input from the basolateral amygdala (BLA), and cortical regions such
as the insular cortex. Divisions of the prefrontal cortex (PFC)- medial PFC (mPFC) and
infralimbic PFC (iPFC) are pivotal sites of consolidation and extinction of fear [19–21]. A
review of this nature would not do justice to the intricacies of the neural circuitry underlying
anxiety and fear, and we recommend [22,23] for those interested in the same.

**Molecular underpinnings of anxiety and fear**

One of the most exciting observations in understanding the translation of mammalian fear to
human anxiety- and fear-related disorders is the shared conservation of the ‘fear reflex’
across all mammals (Figure 2). Seeing that the triggering of anxious and fearful behavior are
stimuli that are perceived as stressful and threatening, it should come as no surprise that
Corticotropin Releasing Factor (CRF) at the apex of the Hypothalamic-Pituitary-Adrenal
axis plays a pivotal role in the manifestation of these states [24,25]. The successful treatment
of anxiety- and fear-related disorders using benzodiazepines and D-cycloserine make a
compelling case for the involvement of neurotransmitters such as GABA and glutamate in
these behavioral states [26–29]. Similarly neuromodulators such as serotonin, dopamine, and
norepinephrine are involved, based on the use of antidepressant medication to treat anxious
and fearful phenotypes. Small molecules like calcitonin gene-related peptide (CGRP),
cholecystokinin (CCK), and the endocannabinoid system are receiving recent attention for
their roles in these disorders [30–32]. We reference [33,34] for a more exhaustive treatment
of the molecules implicated in anxiety and fear.

**Genetic contribution to anxiety and fear**

win studies suggest that the heritable risk of anxiety-related disorders is on the same order of
magnitude as Depression and other moderately heritable psychiatric disorders [35–37]. The
field of anxiety genetics is in the process of gathering sufficiently large sample sizes for
properly powered, hypothesis-neutral, genome-wide association studies of anxiety and its specific subtypes. However, several ongoing large studies of traumatized civilian and military cohorts are beginning to reveal hopeful results that await replication [38,39]. Several studies have investigated the genetic basis of these disorders mostly using SNP analysis of candidate genes. For example, the BDNF (Val66Met) SNP has been associated with anxiety and fear-learning in both humans and rodents [40••, 41]. A recent study from our laboratory emphasized a role for the PACAP-PAC1 receptor in PTSD in females but not males [42••]. The observation that the SNP in the PAC1 receptor most strongly associated with PTSD symptoms resides in a predicted Estrogen Response Element (ERE) points to one potential mechanism for the predominance of PTSD in women. This finding was recently replicated in a separate analysis of physiological responses in children of traumatized patients [43], as well as in a separate cohort examining PTSD symptoms interacting with level of trauma exposure [44]. Notably, a separate independent study [45] conducted with sample populations completely different from those used in [42] did not find an association between the PAC1 gene and PTSD. Such experimental discrepancies emphasize how parameters like population samples, demographics, trauma exposure, and social conditions of the population profoundly influence genome-wide association studies (GWAS). Findings such as these caution us to interpret these GWAS studies strictly within the context of the sample population studied. Some other candidate genes implicated in anxiety- and fear-related disorders are FKBP5, COMT, CCK, and enes associated with the serotonergic system [reviewed in 46]. Given the complexity of anxiety- and fear-related disorders, it would be naïve to assume that a single or only a handful of genes might be involved in their etiology.

**An epigenetic basis for anxiety and fear**

Epigenetic marking of the genome that includes modification of histone proteins and DNA methylation, as well as non-coding RNA based gene targeting, all allow for post-transcriptional regulation of gene expression [47]. Post-natal stress in rats alters the epigenetic signature of the BDNF gene with this effect appearing to persist in subsequent generations [48•]. Noncoding RNAs such as miRNA have been shown to be involved in the extinction of learned fear in rodent models [49•]. While the importance of such epigenetic regulation of gene expression was first elucidated for its role in cancer, more studies are implicating this mechanism in neuropsychiatric disorders [50].

While the information provided thus far does not even begin to delve into the complexities of anxiety-and fear-related disorders, it serves as a skeleton for us to describe how currently used treatments for these disorders, as well as future treatments target biological entities that span from the connectome to the epigenome.

**Therapeutic interventions for anxiety- and fear-related disorders**

**Brain stimulation and optogenetics**

There are many approaches ranging from current therapy and psychopharmacological treatments to future combination and brain-stimulation approaches that hold promise in the treatment of anxiety (Figure 3). Imaging studies have provided evidence to suggest that alteration of brain activity and structure within and between neural circuits plays a critical role in the manifestation of neuropsychiatric disorders [51–53]. Manipulating this altered brain activity using diverse techniques is proving to be a useful therapeutic strategy. Electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS) are some of the strategies used to manipulate neural circuit function [54••]. While they have historically been used in neurological disorders and to ameliorate depressive-like symptoms in Major Depressive
Disorder (MDD), more recent studies emphasize their role in treating anxiety and fear [reviewed by 55••]. However, the main efficacy of these treatments in most of these studies lies in their reversing of co-morbid depression. Most recently more is becoming known about their reversal of the specific symptoms such as hyper-vigilance and arousal associated with anxiety, and cue-specific fear as in PTSD using rodent models [56]. Our current understanding of the mechanisms of action of these treatments speaks to their effect on the firing patterns of neuromodulatory systems in the brain such as the serotonergic and noradrenergic pathways [57]. While more challenging to specifically manipulate, future use of stimulation techniques would do well to affect the balance between excitatory (eg. glutamatergic) and inhibitory (eg. GABergic) drive within specific regions of the brain, which some think is the root cause of anxiety and fear [58].

The recent use of controlling the firing of specific cell populations using light-based manipulation of ion channels termed “optogenetics” provides a glimpse into what the future manipulation and understanding of neural activity in neuropsychiatric illness might look like [59••]. From a basic science perspective, such approaches will give us a firmer appreciation for the specific molecular and neural circuitry involved in anxiety and fear. Further, it may allow us to refine brain coordinates that ought to be stimulated using the more traditionally used stimulation techniques. Treatments using an optogenetic strategy would first necessitate some manner by which to insert into specific brain regions ion channels that could eventually be manipulated by light. In this direction, new advances in bio-safety and bio-engineering ought to make this a reality in the future. For example, manipulation of neural firing using optogenetic methods has already shown to be effective in rodent and non-human primate models of anxiety, fear-learning and depression [60•, 61–63]. More specifically, stimulation of Basolateral Amygdala fibers that project to the Central Amygdala reduced anxiety-like behavior in mice [61]. Such optogenetic approaches allow for more targeted manipulation of neural activity and could potentially reduce side-effects that might arise from the general non-targeted manipulation of activity that is a concern of the currently used stimulation strategies.

Pharmacological intervention

The symptoms of anxiety and fear can be treated in animals and humans to varying degrees of success via administration of benzodiazepines, common antidepressant treatments, and a suite of molecules like buspirone and propranolol that affect serotonergic, dopaminergic and noradrenergic neuromodulation [eg. 26, 64,65]. In several instances chronic treatment is required for their therapeutic efficacy to come to the fore. With respect to reducing fear toward specific stimuli, recent success in both rodent and human models was achieved after the administration of a partial NMDA-receptor agonist, D-cycloserine (DCS) but only after the subjects had also been exposed to an extinction training regimen [27,66,67] (see combinatorial treatment regimens below). Looking to the future, the use of small molecules that cross the blood-brain-barrier and target end-points such as BDNF signaling hold promise [27,28,41,68]. Also, manipulating the epigenetic landscape in anxious and fearful states using drugs that interfere with histone modifications or DNA methylation (eg. HAT inhibitors, HDAC inhibitors, DNMT inhibitors) may provide a fruitful therapeutic strategy [69•, 70]. For example, in mice, overexpression of Histone DeAcetylase2 (HDAC2) has been shown to impair memory processes, with these impairments being reversed after administration of HDAC inhibitors [71].

Cognitive Behavioral Therapy (CBT) and Extinction-based intervention

Most of the success in treating anxiety- and fear-related disorders comes from behavioral therapies that typically involve some form of extinction-based methodology [72]. This could take the form of exposing the subject to the stimulus that triggers fear in the absence of the
negative outcome, or talking about the general state of anxiousness. Another behavioral approach taps into the reconsolidation theory of memory that posits that every time a memory or trigger is recalled, it becomes labile and reconsolidated. Behavioral or pharmacological interventions at this crucial timepoint have been shown to interfere with this reconsolidation [73**, 74*, 75**, 76]. In this direction, virtual reality environments have been especially useful in exposing subjects to environmental triggers [77]. While their mechanisms of action are unknown, the efficacy of lifestyle interventions like diet, exercise, and meditation will undoubtedly come to bear as efficient therapeutic strategies in the treatment of anxiety and fear [78,79].

**Combinatorial treatment regimens**

Given the complexity that underlies disorders like anxiety and fear, it is unlikely that one single form of intervention will be completely successful. What will more likely be needed are treatment regimens that act across several levels. Support for this comes from studies like the one wherein subjects with an intense fear of heights reported less fear after being subjected to a combinatorial treatment regimen that was comprised of virtual-reality extinction-based therapy and DCS administration [27,28,67], as well as the potential mechanisms of combined reconsolidation and extinction [74*, 75**]. With the plethora of potential treatments listed above, the permutations and possibilities for combinatorial treatment are large indeed.

In summary, while a lot has been understood about anxiety and fear from animal models and human case studies, we are only beginning to peel away the layers of complexity associated with these orders. As this happens, we will not only understand new neural mechanisms that go awry in these disorders, but also gain new molecular, anatomical, and behavioral foci that can be targeted with advances in drug design, and technology. Until then a multi-pronged approach that combines basic research in animals, with early diagnosis and intervention in humans will enable these disorders to be treated in a more efficient manner. We believe that due to the translational understanding of fear, which is the basis of anxiety-related disorders, this set of psychiatric syndromes will be the earliest understood at a mechanistic level among common psychiatric illnesses. With current rapid progress in understanding of neural mechanisms of fear and emotion regulation, the future of new and promising approaches is indeed bright.

**Acknowledgments**

This work was supported through NIH ((MH071537 (KJR), MH096764(KJR)) as well as the Burroughs Wellcome Fund. Support was received from the NIH/National Center for Research Resources base grant P51RR000165 to Yerkes National Primate Research Center.

**References**


12. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav. 1997; 31:197–211. [PubMed: 9213134]


40. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006; 314:140–143. [PubMed: 17023662] • An example of translational research wherein a SNP in the BDNF gene was shown to be important for anxiety behavior in humans and rodents. Such an approach is gaining traction as a viable method to investigate the genetic basis of neuropsychiatric disorders.


42. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011; 470:492–497. [PubMed: 21350482] • While the hormonal contribution to the predominance of PTSD in women is well known, this study provides a genetic framework within which to investigate this sex bias. The authors find a SNP within an Estrogen Response Element (ERE) of the Pac1 receptor gene to be associated with PTSD-like symptoms in females but not males.


59. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005; 8:1263–1268. [PubMed: 16116447] • This is among the first papers to utilize an optogenetic approach to control activity in the nervous system. Subsequent literature has built on this work to make this approach more modular, efficient, and amenable to in vivo use.

Approaches outlined herein present a glimpse into what the future application of optogenetics in non-human primates and potentially humans might look like.


69. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150:12–27. [PubMed: 22770212] Most of our knowledge about the role of epigenetics in human disease come from the field of cancer (epi)genomics. Researchers investigating the epigenetic basis of neuropsychiatric disorders and consequent intervention would do well to follow this literature and mimic any therapeutic agents emanating from this field.


<table>
<thead>
<tr>
<th>Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. We highlight new therapies for fear and anxiety from the connectome to epigenome</td>
</tr>
<tr>
<td>2. Optogenetic approaches will potentially be useful to treat fear and anxiety</td>
</tr>
<tr>
<td>3. Drugs that modify the epigenetic landscape hold therapeutic promise</td>
</tr>
<tr>
<td>4. Lifestyle interventions (e.g. diet, exercise, meditation) should be considered</td>
</tr>
<tr>
<td>5. Combinatorial approaches hold the most promise to alleviate fear and anxiety</td>
</tr>
</tbody>
</table>
Figure 1. Structural and Molecular Pathways Involved in Fear and Anxiety
A schematic mammalian brain is shown in which prefrontal cortex (PFC) and sensory cortex interact with hippocampal (HP), bed nucleus of the stria terminalis (BNST), amygdala (AM) and hypothalamic (HYP) circuits to mediate stress, anxiety, and fear responses.

Some molecules implicated in fear and anxiety
- GABA
- CRF
- CGRP
- Glutamate
- eCB
- CCK
- BDNF
- Norepinephrine
- Serotonin

Fear responses towards specific contexts and cues
Stress hyper-responsiveness
Generalized apprehension
Figure 2. The Hard-wired ‘Fear Reflex’ Underlies the Symptoms of Fear and Panic Responses

Neural connectivity between the Central Amygdala outputs (CeA) to brainstem and other subcortical areas activates a known and increasingly well-understood series of pathways which mediate the differential fear reflex patterns that are experienced as a fear or panic-attack in humans with anxiety and fear-related disorders. (modified from [80])
Figure 3. Current and Promising New Approaches to Treatments for Anxiety and Fear-Related Disorders

Currently utilized treatments include antidepressants (targeting serotonin, norepinephrine, and dopamine monoaminergic pathways), GABA-acting benzodiazepines, and beta-adrenergic receptor blockers, as well as cognitive-behavioral therapies. However, all of these treatments have limited efficacy, and new direct and combined treatments specifically targeting known neural pathways underlying fear and anxiety are on the horizon.